Why LUCENTIS?

LUCENTIS is the first and only FDA-approved anti-VEGF* medicine for diabetic retinopathy (DR) with or without diabetic macular edema (DME)

Approximately 1 million doses of LUCENTIS have been given for the treatment of DR with or without DME.

Click on the links below to learn more about how LUCENTIS may be able to help you

Understanding the steps on the DR scale

See improvements on the DR scale

See improvements on an eye chart

*Vascular endothelial growth factor.

Understanding the steps on the DR scale

The DR scale measures whether your DR is getting better or worse.

A 2-step improvement is going from a 7 to a 5, for example. This might mean moving from mild PDR back down to moderately severe NPDR.

People treated with LUCENTIS showed improvements on the DR scale

Two studies showed significant regression, or improvement, of DR with LUCENTIS

Improvements of 2 or more steps were shown in 2 studies of a total of 473 people who had DR with DME after 2 years of treatment:

Improvements of 3 or more steps were shown in the same 2 studies of a total of 473 people who had DR with DME after 2 years of treatment:

In a third study, 189 affected eyes of people who had DR with and without DME were treated monthly with LUCENTIS for 3 months, followed by treatment as required for 2 years:

LUCENTIS can help people who have DR with DME see more letters on an eye chart

In 2 studies of a total of 507 people who had DR with DME after 2 years:

LUCENTIS can also help improve vision in people who have DR with DME

In the same 2 studies, more people who received LUCENTIS monthly were able to read an additional 15 letters on an eye chart at 2 years:

Improvement is defined as reading an additional 15 or more letters on an eye chart.

Patient support for people with DR

Or call 1-866-LUCENTIS (1-866-582-3684), Monday through Friday, 9 AM-8 PM ET.

See how LUCENTIS may help people who have DR with DME